IHS Chemical Week

People & Business :: M&A

Mallinckrodt to acquire Cadence Pharmaceuticals

10:44 AM MST | February 13, 2014 | Natasha Alperowicz

Mallinckrodt, a specialty pharmaceutical and medical imaging group, says that it has entered into a definitive agreement to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00/share in cash, or approximately $1.3 billion. Subject to terms and conditions, the parties expect the transaction to close in mid- to late March. Mallinckrodt says it expects the acquisition to be immediately accretive to its fiscal 2014 adjusted diluted earnings per share and significantly accretive to its fiscal 2015 adjusted diluted earnings per share.   Cadence is...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa